Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778567 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL1404236 | 0.91 | POLB (0.50) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL30056903 | 0.91 | POLB (0.50) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL31554318 | 0.91 | POLB (0.50) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL31554325 | 0.91 | POLB (0.50) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL856302 | 0.90 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL31554373 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL31554355 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL3333110 | 0.87 | LMNA (0.54) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 | |
| SCHEMBL29838479 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN (JP) | 2004-12-02 | — | — | US | claimed |
| EP-1460061-A1 | PROCESS FOR PRODUCING 1-ALKOXYCARBONYL NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-22 | — | — | EP | claimed |
| CN-115974746-B | Synthesis method of tosufloxacin tosylate intermediate | 天地恒一制药股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118055931-A | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023116888-A1 | FIVE- AND SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 杭州多域生物技术有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-115974746-A | Synthetic method of tosufloxacin tosylate intermediate | 天地恒一制药股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-3813819-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3787629-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3601282-A1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178041-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-04 | — | — | WO | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| CN-100351249-C | Quinolinone derivatives as tyrosine kinase inhibitors | CHIRON CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
| CN-1659165-A | Quinolinone derivatives | CHIRON CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1460061-A1 | PROCESS FOR PRODUCING 1-ALKOXYCARBONYL NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| CN-1483028-A | Quinolinone derivatives as tyrosine kinase inhibitors | ϣ | 2004-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | DAO, DDO, ODC1 | SMN1; SMN2 2086/4885LMNA 2851/4885POLB 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.